Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses

Virology

Volumn 403, Issue 2, 2010, Pages 155-162

  Manuel, Edwin R ^a   Wang, Zhongde ^a   Li, Zhongqi ^a   La Rosa, Corinna ^a   Zhou, Wendi ^a   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Deletion site; Insertion site; Intergenic region; Modified vaccinia Ankara; Recombinant vaccine; Stability

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SPACER DNA; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENETIC STABILITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION SITE; VIRUS GENOME; VIRUS PARTICLE;

ANIMALS; ANTIGENS; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VACCINES; DNA, INTERGENIC; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINIA VIRUS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; MUS;

EID: 77953364365     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.04.015     Document Type: Article

References (45)

1. Amato R.J., Shingler W., Goonewardena M., de Belin J., Naylor S., Jac J., Willis J., Saxena S., Hernandez-McClain J., Harrop R. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J. Immunother. 2009, 32:765-772.
2. Burgers W.A., Shephard E., Monroe J.E., Greenhalgh T., Binder A., Hurter E., Van Harmelen J.H., Williamson C., Williamson A.L. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res. Hum. Retroviruses 2008, 24:195-206.
3. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of beta- galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 1985, 5:3403-3409.
4. Diamond D.J., York J., Sun J., Wright C.L., Forman S.J. Development of a candidate HLA A0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997, 90:1751-1767.
5. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 1998, 79(Pt 2):347-352.
6. Drexler I., Staib C., Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr. Opin. Biotechnol. 2004, 15:506-512.
7. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Montefiori D.C., Byrum R., Piatak M., Lifson J.D., Amara R.R., Robinson H.L., Huggins J.W., Moss B. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 2007, 366:84-97.
8. Earl P.L., Cotter C., Moss B., Vancott T., Currier J., Eller L.A., McCutchan F., Birx D.L., Michael N.L., Marovich M.A., Robb M., Cox J.H. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 2009, 27:5885-5895.
9. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., Kuiken C., Haynes B., Letvin N.L., Walker B.D., Hahn B.H., Korber B.T. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 2007, 13:100-106.
10. Gherardi M.M., Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J. Gen. Virol. 2005, 86:2925-2936.
11. Gomez C.E., Najera J.L., Jimenez E.P., Jimenez V., Wagner R., Graf M., Frachette M.J., Liljestrom P., Pantaleo G., Esteban M. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007, 25:2863-2885.
12. Gomez C.E., Najera J.L., Krupa M., Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 2008, 8:97-120.
13. Hodge J.W., Poole D.J., Aarts W.M., Gomez Y.A., Gritz L., Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 2003, 63:7942-7949.
14. Howley P and Leyrer S. Intergenic regions as insertion sites in the genome of modified vaccinia ankara (MVA). Bavarian Nordic A/S. 10/514,761(7,550,147 B2), 1-40. 6-23-2009. Kvistgaard/DK. 5-14-2003.
15. Howley P.M., Spehner D., Drillien R. A vaccinia virus transfer vector using a GUS reporter gene inserted into the I4L locus. Gene 1996, 172:233-237.
16. Howley P.M., Spehner D., Drillien R. A vaccinia virus transfer vector using a GUS reporter gene inserted into the I4L locus. Gene 1996, 172:233-237.
17. Johnson R.P., Trocha A., Yang L., Mazzara G.P., Panicali D.L., Buchanan T.M., Walker B.D. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 1991, 147:1512-1521.
18. Krishnan A., Wang Z., Srivastava T., Rawal R., Manchanda P., Diamond D.J., La Rosa C. A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. Immunol. Lett. 2008, 120:108-116.
19. La Rosa C., Wang Z., Lacey S.F., Lalimarmo M.M., Krishnan A., Longmate J., Diamond D.J. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp. Hematol. 2006, 34:497-507.
20. Maruyama H., Zaloudik J., Li W., Sperlagh M., Koido T., Somasundaram R., Scheck S., Prewett M., Herlyn D. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol. Immunother. 2000, 49:123-132.
21. Mayr A., Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev. Biol. Stand. 1978, 41(225-34):225-234.
22. McLaughlin-Taylor E., Pande H., Forman S.J., Tanamachi B., Li C.R., Zaia J.A., Greenberg P.D., Riddell S.R. Identification of the major late human cytomegalovirus matrix protein pp 65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J. Med. Virol. 1994, 43:103-110.
23. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72(Pt 5):1031-1038.
24. Meyer R.G., Britten C.M., Siepmann U., Petzold B., Sagban T.A., Lehr H.A., Weigle B., Schmitz M., Mateo L., Schmidt B., Bernhard H., Jakob T., Hein R., Schuler G., Schuler-Thurner B., Wagner S.N., Drexler I., Sutter G., Arndtz N., Chaplin P., Metz J., Enk A., Huber C., Wolfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol. Immunother. 2005, 54:453-467.
25. Mooij P., Nieuwenhuis I.G., Knoop C.J., Doms R.W., Bogers W.M., Ten Haaft P.J., Niphuis H., Koornstra W., Bieler K., Kostler J., Morein B., Cafaro A., Ensoli B., Wagner R., Heeney J.L. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J. Virol. 2004, 78:3333-3342.
26. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:11341-11348.
27. Moss B., Earl P.L. Expression of proteins in mammalian cells using vaccinia virus vectors. Current Protocols in Immunology 1998, 16.15.1-16.21.9. Greene Publishing, New York. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E. Shevach, W. Strober (Eds.).
28. Nagai T., Ibata K., Park E.S., Kubota M., Mikoshiba K., Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 2002, 20:87-90.
29. Nemeckova S., Hainz P., Otahal P., Gabriel P., Sroller V., Kutinova L. Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells. Acta Virol. 2001, 45:243-247.
30. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 1997, 185:2043-2051.
31. Ramirez J.C., Gherardi M.M., Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation. J. Virol. 2000, 74:923-933.
32. Rochester S.C., Traktman P. Characterization of the single-stranded DNA binding protein encoded by the vaccinia virus I3 gene. J. Virol. 1998, 72:2917-2926.
33. Schmelz M., Sodeik B., Ericsson M., Wolffe E.J., Shida H., Hiller G., Griffiths G. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J. Virol. 1994, 68:130-147.
34. Timm A., Enzinger C., Felder E., Chaplin P. Genetic stability of recombinant MVA-BN. Vaccine 2006, 24:4618-4621.
35. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., Daftarian P., Longmate J., Britt W.J., Diamond D.J. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol. 2004, 78:3965-3976.
36. Wang Z., La Rosa C., Mekhoubad S., Lacey S.F., Villacres M.C., Markel S., Longmate J., Ellenhorn J.D., Siliciano R.F., Buck C., Britt W.J., Diamond D.J. Attenuated Poxviruses Generate Clinically Relevant Frequencies of CMV-Specific T cells. Blood 2004, 104:847-856.
37. Wang Z., La Rosa C., Lacey S.F., Maas R., Mekhoubad S., Britt W.J., Diamond D.J. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J. Clin. Virol. 2006, 35:324-331.
38. Wang Z., La Rosa C., Li Z., Ly H., Krishnan A., Martinez J., Britt W.J., Diamond D.J. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp 65 and IE1. Vaccine 2007, 25:1132-1141.
39. Wang Z., Zhou W., Srivastava T., La Rosa C., Mandarino A., Forman S.J., Zaia J.A., Britt W.J., Diamond D.J. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology 2008, 377:379-390.
40. Wang Z., Martinez J., Zhou W., La Rosa C., Srivastava T., Dasgupta A., Rawal R., Li Z., Britt W.J., Diamond D. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 2010, 28:1547-1557.
41. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., Sissons J.G. The human CTL response to cytomegalovirus is dominanted by structural protein pp 65: Frequency, specificity, and T Cell Receptor usage of pp65-Specific CTL. J. Virol. 1996, 70:7569-7579.
42. Wyatt L.S., Belyakov I.M., Earl P.L., Berzofsky J.A., Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008, 372:260-272.
43. Wyatt L.S., Earl P.L., Xiao W., Americo J.L., Cotter C.A., Vogt J., Moss B. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J. Virol. 2009, 83:7176-7184.
44. Young M.D., Schneider D.L., Zuckerman A.J., Du W., Dickson B., Maddrey W.C. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology 2001, 34:372-376.
45. Yue Y., Wang Z., Abel K., Li J., Strelow L., Mandarino A., Eberhardt M.K., Schmidt K.A., Diamond D.J., Barry P.A. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med. Microbiol. Immunol. 2008, 197:117-123.